Dr. Arkadiusz Dudek, MD
Claim this profileRegions Cancer Care Center
Studies Lung Cancer
Studies Solid Tumors
14 reported clinical trials
23 drugs studied
Area of expertise
1Lung Cancer
Stage IV
Stage III
ALK positive
2Solid Tumors
Stage IV
Stage III
ALK positive
Affiliated Hospitals
Clinical Trials Arkadiusz Dudek, MD is currently running
DF6002 + Nivolumab
for Advanced Cancer
This trial is testing a new drug, DF6002, alone and with an existing drug, Nivolumab, in patients with advanced solid tumors. These patients have cancers that are hard to treat with standard methods. DF6002 might help shrink or slow down tumors, while Nivolumab boosts the immune system to fight cancer.
Recruiting1 award Phase 15 criteria
Repotrectinib
for Solid Tumors
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary objective will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.
Recruiting1 award Phase 1 & 27 criteria
More about Arkadiusz Dudek, MD
Clinical Trial Related5 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Arkadiusz Dudek, MD has experience with
- Pembrolizumab
- Nivolumab
- Pemetrexed
- Durvalumab
- Carboplatin
- Repotrectinib (TPX-0005)
Breakdown of trials Arkadiusz Dudek, MD has run
Lung Cancer
Solid Tumors
Melanoma
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Arkadiusz Dudek, MD specialize in?
Arkadiusz Dudek, MD focuses on Lung Cancer and Solid Tumors. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Arkadiusz Dudek, MD currently recruiting for clinical trials?
Yes, Arkadiusz Dudek, MD is currently recruiting for 3 clinical trials in Saint Paul Minnesota. If you're interested in participating, you should apply.
Are there any treatments that Arkadiusz Dudek, MD has studied deeply?
Yes, Arkadiusz Dudek, MD has studied treatments such as Pembrolizumab, Nivolumab, Pemetrexed.
What is the best way to schedule an appointment with Arkadiusz Dudek, MD?
Apply for one of the trials that Arkadiusz Dudek, MD is conducting.
What is the office address of Arkadiusz Dudek, MD?
The office of Arkadiusz Dudek, MD is located at: Regions Cancer Care Center, Saint Paul, Minnesota 55303 United States. This is the address for their practice at the Regions Cancer Care Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.